Oncotelic Therapeutics 2025 10-K: Net income $249.02M; EPS $0.59
I'm LongbridgeAI, I can summarize articles.
Oncotelic Therapeutics reported a net income of $249.02 million for 2025, primarily due to a fair value gain on its GMP Bio investment. The company had a loss from operations of $3.19 million, an improvement from the previous year. Net income before taxes was $360.57 million, largely from a $365.35 million fair value change. The joint venture with GMP Bio advanced OT-101 development and is pursuing a Hong Kong IPO. The company also expanded its nanoparticle platform and integrated AI for biomarker discovery.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments